Singular Genomics Systems, INC Form 4 insider transactions

Chief Financial Officer Dalen Meeter of Singular Genomics Systems, Inc. reports the acquisition of 500 shares of common stock through the settlement of vested Restricted Stock Units (RSUs) on August 9, 2024.

Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, Inc., reports the acquisition of 500 shares of common stock through the settlement of vested Restricted Stock Units.

Chief Financial Officer of Singular Genomics Systems, Dalen Meeter, reports the acquisition and disposal of common stock and settlement of vested Restricted Stock Units (RSUs).

Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, recently exercised stock options, acquiring 7,500 shares of common stock.

CEO Andrew Spaventa reports acquisition and disposal of Singular Genomics Systems (OMIC) stock, including shares from vested Restricted Stock Units (RSUs) and gifts to a living trust.

Marcia Eisenberg, a director at Singular Genomics Systems, acquired stock options exercisable for 55,500 shares of common stock.

Director Elaine R. Mardis acquired 74,000 stock options in Singular Genomics Systems, Inc. on May 29, 2024.

Kim P. Kamdar, a director of Singular Genomics Systems, Inc., acquired 74,000 stock options on May 29, 2024, exercisable at $0.372 per share.

Director David L. Barker acquired 74,000 stock options in Singular Genomics Systems, Inc. on May 29, 2024.

Jason Ryan, a director at Singular Genomics Systems, acquired 74,000 stock options on May 29, 2024, exercisable at $0.372 per share.

Michael J. Pellini, a director of Singular Genomics Systems, acquired stock options for 100,000 shares on May 29, 2024.

Jyotsna Ghai, Chief Operating Officer of Singular Genomics Systems, reports the acquisition and disposal of company stock and restricted stock units.

Dalen Meeter, CFO of Singular Genomics Systems, Inc., reports the settlement of vested Restricted Stock Units (RSUs) resulting in the acquisition of 15,000 shares of Common Stock.

Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, acquired 15,000 shares of common stock through the settlement of vested Restricted Stock Units (RSUs) on May 9, 2024.

CEO Andrew Spaventa reports the acquisition and disposal of Singular Genomics Systems, Inc. common stock related to the vesting and gifting of Restricted Stock Units.

Chief Commercial Officer Sam Ropp of Singular Genomics Systems, Inc. reports the vesting and disposal of restricted stock units (RSUs) and acquisition of common stock on March 15, 2024.

Chief Financial Officer of Singular Genomics Systems, Dalen Meeter, reports the vesting and settlement of restricted stock units (RSUs) into common stock.

Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, Inc., reports the acquisition of 7,500 shares of common stock through the exercise of restricted stock units.

CEO Andrew Spaventa reports the vesting and gifting of shares, along with adjustments to previously reported holdings.